Predicting the Response of Treatment in Cardiomyopathy

Not Applicable

Recruiting

• Conditions: Idiopathic Dilated Cardiomyopathy; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12611000146998
• Lead Sponsor: Professor Joseph Selvanayagam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-02-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Clinical heart failure (New York Heart Association class II - IV) on first presentation, LV ejection fraction <45% as measured by echocardiography, ventriculography, or cardiac
scintigraphy

Exclusion Criteria

Standard MRI contraindications, including permanent pacemaker, implantable defibrillator,
severe claustrophobia, Significant coronary artery disease, as manifest by >70% stenosis in a major epicardial
coronary artery or the presence of a moderate or greater zone of ischaemia/infarction on
stress imaging, Concomitant valvular heart disease as a cause or central contributor to the heart failure
(excluding functional mitral regurgitation, Hypertrophic obstructive cardiomyopathy, Myocarditis, amyloidosis, sarcoidosis, uncontrolled thyroid disease, post-partum
cardiomyopathy, Renal impairment (eGFR <60ml/min) will be an exclusion criterion from the administration
of gadolinium, New York Heart Association class IV symptoms (i.e. dyspnoea at rest), and unstable
ischaemic heart disease will be exclusion criteria from cardiopulmonary exercise testing

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary aim of the project is to measure the prognostic significance of myocardial fibrosis in new presentation idiopathic dilated cardiomyopathy (DCM) using cardiac magnetic resonance (CMR).[Baseline, 6 months and 12 months]

Secondary Outcome Measures

Name	Time	Method
Determine the prevalence, severity and prognostic significance of inter- and intra-left ventricular mechanical dyssynchrony in new presentation DCM using advanced echocardiography techniques.[Baseline, 6 months and 12 months];Assess the utility of serum biomarkers of myocardial fibrosis, such as matrix metalloproteinases (MMPs) and the tissue inhibitors of matrix metalloproteinase (TIMPs), in the prediction of prognosis in new presentation DCM.[Baseline, 6 months and 12 months]